Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans.
about
Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirusAntibiotic alternatives: the substitution of antibiotics in animal husbandry?SslE elicits functional antibodies that impair in vitro mucinase activity and in vivo colonization by both intestinal and extraintestinal Escherichia coli strainsCharacterization of heat-stable (STa) toxoids of enterotoxigenic Escherichia coli fused to double mutant heat-labile toxin peptide in inducing neutralizing Anti-STa antibodies.Experimental infection of healthy volunteers with enterotoxigenic Escherichia coli wild-type strain TW10598 in a hospital ward.Toxicity and immunogenicity of Enterotoxigenic Escherichia coli heat-labile and heat-stable toxoid fusion 3xSTa(A14Q)-LT(S63K/R192G/L211A) in a murine model.Designing vaccines to neutralize effective toxin delivery by enterotoxigenic Escherichia coli.Contribution of the highly conserved EaeH surface protein to enterotoxigenic Escherichia coli pathogenesis.Conservation and immunogenicity of novel antigens in diverse isolates of enterotoxigenic Escherichia coli.Genetic fusions of a CFA/I/II/IV MEFA (multiepitope fusion antigen) and a toxoid fusion of heat-stable toxin (STa) and heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC) retain broad anti-CFA and antitoxin antigenicity.Combination vaccines against diarrheal diseases.Development of safe, effective and immunogenic vaccine candidate for diarrheagenic Escherichia coli main pathotypes in a mouse modelCurrent Progress in Developing Subunit Vaccines against Enterotoxigenic Escherichia coli-Associated Diarrhea.A multiepitope fusion antigen elicits neutralizing antibodies against enterotoxigenic Escherichia coli and homologous bovine viral diarrhea virus in vitro.Antibodies derived from an enterotoxigenic Escherichia coli (ETEC) adhesin tip MEFA (multiepitope fusion antigen) against adherence of nine ETEC adhesins: CFA/I, CS1, CS2, CS3, CS4, CS5, CS6, CS21 and EtpA.Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli.Dynamic Interactions of a Conserved Enterotoxigenic Escherichia coli Adhesin with Intestinal Mucins Govern Epithelium Engagement and Toxin DeliveryA Novel Protective Vaccine Antigen from the Core Escherichia coli Genome.Multiepitope fusion antigen induces broadly protective antibodies that prevent adherence of Escherichia coli strains expressing colonization factor antigen I (CFA/I), CFA/II, and CFA/IV.Pathogenicity and phenotypic characterization of enterotoxigenic Escherichia coli isolates from a birth cohort of children in rural Egypt.EatA, an immunogenic protective antigen of enterotoxigenic Escherichia coli, degrades intestinal mucin.Enterotoxigenic Escherichia coli secretes a highly conserved mucin-degrading metalloprotease to effectively engage intestinal epithelial cells.Murine immunization with CS21 pili or LngA major subunit of enterotoxigenic Escherichia coli (ETEC) elicits systemic and mucosal immune responses and inhibits ETEC gut colonization.Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407Passive antibodies derived from intramuscularly immunized toxoid fusion 3xSTaN12S-dmLT protect against STa+ enterotoxigenic Escherichia coli (ETEC) diarrhea in a pig model.Enterotoxigenic Escherichia coli heat-stable toxin and heat-labile toxin toxoid fusion 3xSTaN12S-dmLT induces neutralizing anti-STa antibodies in subcutaneously immunized mice.MEFA (multiepitope fusion antigen)-Novel Technology for Structural Vaccinology, Proof from Computational and Empirical Immunogenicity Characterization of an Enterotoxigenic Escherichia coli (ETEC) Adhesin MEFA.Design and characterization of a chimeric multiepitope construct containing CfaB, heat-stable toxoid, CssA, CssB, and heat-labile toxin subunit B of enterotoxigenic Escherichia coli: a bioinformatic approach.Enterotoxigenic Escherichia coli (ETEC) adhesin-toxoid MEFA (multiepitope fusion antigen) CFA/I/II/IV-3xSTaN12S-mnLTG192G/L211A derived antibodies inhibit adherence of seven adhesins (CFA/I, CFA/II & CFA/IV), neutralize enterotoxicity of both toxinsNeutralizing Anti-Heat-Stable Toxin (STa) Antibodies Derived from Enterotoxigenic Escherichia coli Toxoid Fusions with STa Proteins Containing N12S, L9A/N12S, or N12S/A14T Mutations Show Little Cross-Reactivity with Guanylin or Uroguanylin.A Chimeric protein of CFA/I, CS6 subunits and LTB/STa toxoid protects immunized mice against enterotoxigenic Escherichia coli.Co-administered Tag-Less Toxoid Fusion 3xSTaN12S-mnLTR192G/L211A and CFA/I/II/IV MEFA (Multiepitope Fusion Antigen) Induce Neutralizing Antibodies to 7 Adhesins (CFA/I, CS1-CS6) and Both Enterotoxins (LT, STa) of Enterotoxigenic Escherichia coli (ETImpact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteers.Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016
P2860
Q26995690-C7AD496B-A36F-4F9A-A142-903D9D20F07DQ27027984-E3F00287-8020-4A76-B228-6C99E3DE8F96Q27325713-C70E4547-3345-4F81-8F51-6BC1EB785F85Q30409778-63FAE621-F4FC-4D6F-AC4D-855658C4CED7Q30410648-813F235A-AA51-4D5F-8048-20F0ACC1A6BEQ30416787-43145DD8-E876-4A40-9FE2-8D2EEA84B96AQ33813634-1F03A579-4E8C-4DA8-80DD-2D964702106EQ34298466-B52C41A2-65B7-42E3-8742-F639DDC48D0EQ35023488-968934C1-9393-44BC-AD4D-2DDCA5D211BDQ35213355-B38E6CC8-FA86-4601-A4E0-0B64D09E564AQ35896237-154E1533-6549-4196-9D20-43DF02F7906CQ35918800-8355482C-2796-4518-8CB5-5023DFC59B05Q35998767-6E4A1C86-9180-4466-B9BA-1DF987D4CAF1Q36970290-212B484E-AC1C-4764-8882-DB0AA59FB0C9Q37057975-200127B2-BAC1-437F-84E2-A2436E7A1454Q37335500-9BBB1F43-D82F-4A95-99A7-427F409C81C9Q37425033-145B9CAC-61E6-4CDF-98AF-D1BCCF60F90FQ37430612-D79A4395-C098-4182-9329-2658AA46477AQ37545078-52897506-70BC-4F73-8FAD-72FA798317D5Q37546154-A5D7EE13-22D3-4A4C-BFF5-B51A7CF47AB8Q37546427-3146E01B-EDA5-4DD5-8871-77326F5F37CDQ37546507-898D4D50-8C64-4632-8C21-4BCD456EDC58Q38908041-D52A66B7-EC2C-431B-AF78-0C5A040C79DEQ38941412-5CD2F254-F31B-4897-AEBC-76324766FBD6Q39065850-710A0BF9-D5B2-4E3D-9589-376A5A85FCDDQ39218689-41703A50-50DE-4E04-B5DD-4A6CA7942BDEQ41715897-CB14C234-4294-41A4-ABC7-1581C7E2E6D3Q43472318-42A04FD8-66A4-4C07-921B-852FB9725379Q47269501-0F1E8AF1-C53D-45E8-8C5B-D16A5F360744Q47592750-49D8AB28-C6F6-41CB-9FA9-25E6F4B51DF1Q47753043-43CA1051-F7F4-4DCB-B440-4B72CA1D4CADQ55315300-9B34037D-228E-46D2-A00B-79569D58FF70Q55322314-004CA5FF-88CF-4348-9D36-4E392F0FB13FQ57927103-33BC781F-4097-4B3B-AD97-4C0E247DE734
P2860
Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Progress and hurdles in the de ...... ic Escherichia coli in humans.
@en
type
label
Progress and hurdles in the de ...... ic Escherichia coli in humans.
@en
prefLabel
Progress and hurdles in the de ...... ic Escherichia coli in humans.
@en
P2860
P356
P1476
Progress and hurdles in the de ...... ic Escherichia coli in humans.
@en
P2093
Weiping Zhang
P2860
P304
P356
10.1586/ERV.12.37
P577
2012-06-01T00:00:00Z